Edison Oncology Lead Programs
OROTECAN®
(oral irinotecan HCI)
Pediatric & Adult Malignancies
Human clinical safety and PK established
Pre-Clinical
PHASE 1-2 CLINICAL TRIALS
PIVOTAL
REGISTRATION-DIRECTED
CLINICAL TRIALS
FDA MARKETING APPROVAL
EO-3001
ARID1a Targeted Therapy
Clear Cell Ovarian Cancer & Solid Tumors
Human clinical safety and PK established
Pre-Clinical
PHASE 1-2 CLINICAL TRIALS
PIVOTAL
REGISTRATION-DIRECTED
CLINICAL TRIALS
FDA MARKETING APPROVAL
EO-4426
Tezacitabine
Solid Tumors & Hematologic Malignancies
Human clinical safety and PK established
Pre-Clinical
PHASE 1-2 CLINICAL TRIALS
PIVOTAL
REGISTRATION-DIRECTED
CLINICAL TRIALS
FDA MARKETING APPROVAL
Edison Oncology Partnered Programs
EO-1001
panErbB inhibitor
Solid Tumors
Pre-Clinical
PHASE 1-2 CLINICAL TRIALS
PIVOTAL
REGISTRATION-DIRECTED
CLINICAL TRIALS
FDA MARKETING APPROVAL
DNA-DAMAGE RESPONSE INHIBITORS
Solid Tumors
Pre-Clinical
PHASE 1-2 CLINICAL TRIALS
PIVOTAL
REGISTRATION-DIRECTED
CLINICAL TRIALS
FDA MARKETING APPROVAL
Our Pipeline – Lead Programs
Orotecan®:
Orotecan is a novel, patented oral formulation of irinotecan, a major cancer therapy. Orotecan has been developed in collaboration with leading cancer clinicians to improve tolerability and patient compliance in the treatment of rare childhood tumors, with an opportunity to expand into major adult cancers.
EO3001 - mitochondrial targeting agent:
EO3001 was studied in prior clinical trials involving more than 1,000 cancer patients. We have identified biomarker-circumscribed orphan cancer population that we believe will benefit from treatment with EO3001. Edison Oncology has filed new patents related to these discoveries.
Our Pipeline – Partner Programs
EO1001:
EO1001 is partnered with Apollomics Inc. EO1001 is a novel, irreversible pan-erbB inhibitor with excellent brain penetration offering the potential for improved efficacy for non-small cell lung cancer (NSCLC) and breast cancer patients with treatment-resistant disease, including brain metastasis. Edison Oncology has initiated the regulatory filing process and plans to initiate human clinical trials with EO1001 during 2021
DNA-damage repair inhibitors:
Edison Oncology has a significant minority interest in Rakovina Therapeutics Inc. (TSX-V: RKV), a company focused on the development of new cancer treatments based on novel DNA-damage response technologies. Edison Oncology has assigned rights to its pre-clinical EO2000 series of novel of poly(ADP-ribose) polymerase (PARP) inhibitors to Rakovina Therapeutics.
Business Development Opportunities
Please contact us if you are interested in business opportunities.
Careers
Join our team! Visit our website to view available opportunities and apply now.
Investors
All prospective investors, please contact us if you are interested in learning more.